zuranolone: Clinical Trials

6 completed, 2 terminated. 8 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	8	Completed 6, Terminated 2

Follow zuranolone: new trials by email Literature Review of zuranolone trials Research Report on zuranolone

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder SAGE-217, Matching Placebo, Sertraline - Depressive Disorder, Major	Phase 3	Completed	Biogen	440	2020-11-09	2023-12-22
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) SAGE-217, Placebo - Depression, Postpartum	Phase 3	Completed	Biogen	200	2020-06-08	2023-11-30
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) SAGE-217, Placebo - Depressive Disorder, Major	Phase 3	Completed	Biogen	543	2020-05-12	2023-12-22
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder SAGE-217, Placebo - Major Depressive Disorder	Phase 3	Terminated	Biogen	53	2019-08-06	2023-11-29
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) SAGE-217 - Major Depressive Disorder	Phase 3	Completed	Biogen	1515	2019-02-27	2024-08-27
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia SAGE-217, Placebo - Major Depressive Disorder, Insomnia	Phase 3	Terminated	Biogen	87	2019-02-04	2023-11-29
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder SAGE-217, Placebo - Major Depressive Disorder	Phase 3	Completed	Biogen	581	2018-11-19	2023-11-29
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules - Postpartum Depression	Phase 3	Completed	Biogen	276	2017-01-04	2023-12-15

Conditions studied

Depressive Disorder, Major (6)  ·  Depression, Postpartum (2)  ·  Depression (1)  ·  Depressive Disorder (1)  ·  Sleep Initiation and Maintenance Disorders (1)

Sponsors

Biogen (8)

Countries

United States (8)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 34190962, PMID 36724109, PMID 36811520, PMID 37491938, PMID 37875578, PMID 38153320

NIH funding

2019 (1)